It was marketed under the brand name Byetta and got approval in 2005
Prescribers seeking evidence-based guidance on the neuropsychiatric or affective side effect profile of GLP-1 receptor agonists, including semaglutide, should refer to the published regulatory safety communications from the FDA and EMA, the SUSTAIN and STEP trial data, and peer-reviewed pharmacovigilance literature examining anhedonia, mood changes, and related adverse events in this drug class
It can help dull and uneven areas appear softer over time
Together these modifications extend the circulating half-life from roughly 2 minutes (native GLP-1) to approximately 7 days, enabling once-weekly research dosing
Indiana Capital Chronicle maintains editorial independence
If symptoms are particularly severe following a dose increase, discuss with your prescriber whether slowing the titration schedule might be appropriate